Pneumococcal vaccines in adults: Assessing the evolving evidence

Vaccine

Volumn 29, Issue 37, 2011, Pages 6149-6154

  Grabenstein, John D ^a   Manoff, Susan B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Conjugate vaccines; Immunization; Pneumococcal vaccines; Policy; Polysaccharide vaccines; Streptococcus pneumoniae; Vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

DRUG EFFICACY; IMMUNOLOGY; NOTE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PUBLIC HEALTH; SEROTYPE; VACCINATION;

ADULT; HUMANS; IMMUNIZATION; IMMUNOLOGIC MEMORY; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 80051559679     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.116     Document Type: Note

References (36)

1. Soneji S., Metlay J. Mortality reductions for older adults differ by race/ethnicity and gender since the introduction of adult and pediatric pneumococcal vaccines. Public Health Rep 2011, 126(March-April):259-269.
2. Fedson D, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, et al. 23-valent pneumococcal polysaccharide vaccination for adults: New perspectives for Europe. Expert Rev Vaccines, 10(August); in press.
3. Fisman D.N., Abrutyn E., Spaude K.A., Kim A., Kirchner C., Daley J. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 2006, 42(April 15):1093-1101.
4. Johnstone J., Marrie T.J., Eurich D.T., Majumdar S.R. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007, 167(October 8):1938-1943.
5. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2008. http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD000422/frame.html.
6. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Active bacterial core surveillance/emerging infections program network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
7. Musher D.M., Manoff S.B., Liss C., McFetridge R.D., Marchese R.D., Bushnell B., et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010, 201(February 15):516-524.
8. Manoff S.B., Liss C., Caulfield M.J., Marchese R.D., Silber J., Boslego J., et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged >65 years. J Infect Dis 2010, 201(February 15):525-533.
9. Musher DM, Manoff SB, McFetridge RD, Liss C, Marchese RD, Raab J, et al. Antibody persistence 10 years after 1st and 2nd doses of 23-valent pneumococcal polysaccharide Vaccine, and immunogenicity and safety of 2nd and 3rd doses in older adults. Hum Vaccines, 7; in press.
10. Hammitt L.L., Bulkow L.R., Singleton R.J., Nuorti J.P., Hummel K.B., Miernyk K.M., et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011, 29(March 9):2287-2295.
11. Advisory Committee on Immunization Practices. Pneumococcal polysaccharide vaccine. MMWR 1997; 46(RR-8):1-24. ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/rr4608.pdf.
12. Maruyama T., Taguchi O., Niederman M.S., Morser J., Kobayashi H., Kobayashi T., et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: Double blind, randomised and placebo controlled trial. BMJ 2010, 340(March 8). c1004 (1-7).
13. Crum-Cianflone N.F., Huppler Hullsiek K., Roediger M., Ganesan A., Patel S., Landrum M.L., et al. Infectious disease clinical research program HIV working group. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis 2010, 202(October 1):1114-1125.
14. de Roux A., Schmöle-Thoma B., Siber R.G., Hackell J.G., Kuhnke A., Ahlers N., et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008, 46(April 1):1015-1023. [erratum 1488].
15. Dransfield M.T., Nahm M.H., Han M.K., Harnden S., Criner G.J., Martinez F.J., et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180(September 15):499-505.
16. Goldblatt D., Southern J., Andrews N., Ashton L., Burbidge P., Woodgate S., et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009, 49:1318-1325.
17. Jackson L.A., Neuzil K.M., Nahm M.H., Whitney C.G., Yu O., Nelson J.C., et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007, 25(May 16):4029-4037.
18. Lazarus R., Clutterbuck E., Yu L.-M., Bowman J., Bateman E.A., Diggle L., et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis 2011, 52(March 15):736-742.
19. Miernyk K.M., Butler J.C., Bulkow L.R., Singleton R.J., Hennessy T.W., Dentinger C.M., et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in Alaska native adults 55-70 years of age. Clin Infect Dis 2009, 49(July 15):241-248.
20. Musher D.M., Rueda A.M., Nahm M.H., Graviss E.A., Rodriguez-Barradas M.C. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008, 198(October 1):1019-1027.
21. Peñaranda M., Payeras A., Cambra A., Mila J., Riera M. Majorcan Pneumococcal Study Group. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults. AIDS 2010, 24(May 15):1226-1228.
22. Ridda I., Macintyre C.R., Lindley R., Gao Z., Sullivan J.S., Yuan F.F., et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009, 27:1628-1636. [erratum 6649].
23. Musher D.M., Sampath R., Rodriguez-Barradas M.C. The potential role for protein-conjugate pneumococcal vaccine in adults: What is the supporting evidence?. Clin Infect Dis 2011, 52(March):633-640.
24. Baxendale H.E., Johnson M., Keating S.M., Ashton L., Burbidge P., Woodgate S., et al. Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination. Vaccine 2010, 28(October 4):6915-6922.
25. Baxendale H.E., Keating S.M., Johnson M., Southern J., Miller E., Goldblatt D. The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly. Vaccine 2010, 28(July 5):4763-4770.
26. Advisory Committee on Immunization Practices Updated recommendations for use of meningococcal conjugate vaccines. MMWR 2011, 60(January 28):72-76. http://www.cdc.gov/mmwr/pdf/wk/mm6003.pdf.
27. Nichol K.L. Pneumococcal vaccination and revaccination in the elderly population. J Infect Dis 2010, 201:659-661.
28. Slifka M.K., Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998, 10(June):252-258.
29. Defrance T., Taillardet M., Genestier L. T cell-independent B cell memory. Curr Opin Immunol 2011, 23(June):330-336.
30. Heidelberger M., DiLapi M.M., Siegel M., Walter A.W. Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. J Immunol 1950, 65(November):535-541.
31. Jackson L.A., Benson P., Sneller V.P., Butler J.C., Thompson R.S., Chen R.T., et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999, 281(January 20):243-248.
32. Törling J., Hedlund J., Konradsen H.B., Ortqvist A. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003, 22(December 8):96-103.
33. Advisory Committee on Immunization Practices Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR 2010, 59(September 3):1102-1106. http://www.cdc.gov/mmwr/PDF/wk/mm5934.pdf.
34. O'Brien K.L. Pneumococcal conjugate vaccine, polysaccharide vaccine, or both for adults? We're not there yet. Clin Infect Dis. 2009, 49(November 1):1326-1328. [editorial].
35. Väkeväinen M., Soininen A., Lucero M., Nohynek H., Auranen K., Mäkelä P.H., et al. ARIVAC Consortium. Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination. J Pediatr 2010, 157:778-783.
36. Dagan R., Givon-Lavi N., Greenberg D., Fritzell B., Siegrist C.A. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010, 201(May 15):1570-1579.